Blog

The outcomes from the July 2014 PBAC meeting have been added to the MAESTrO Australia PBAC database. ...

[:content [\T \h \e \space \P \B \A \C \space \w \i \l \l \space \c \o \n \s \i \d \e \r \space \5 \3 \space \s \u \b \m \i \s \s \i \o \n \s \space \( \3 \1 \m \a \j \o \r \space \& \space \2 \2 \space \m \i \n \o \r \) \space \a \t \space \i \t \s \space \n \e \x \t \space \s \c \h \e \d \u \l \e \d \space \m \e \e \t \i \n \g \space \i \n \space \M \a \r \c \h \. \  " ..."]]

As PBAC Chair I am deeply concerned by Alexion’s response to the Minister’s approval of funding for Soliris for the ...

[:content [\4 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \- \space \T \h \e \space \M \A \E \S \T \r \O \space \d \a \t \a \b \a \s \e \space \i \s \space \n \o \w \space \h \o \u \s \e \d \space \o \n \space \a \space \l \o \c \a \l \space \s \e \r \v \e \r \. \space \S \u \b \s \c \r \i \b \e \r \s \space \s \h \o \u \l \d \space \n \o \t \i \c \e \space \a \space \s \i \g \n \i \f \i \c \a \n \t \  \i \m \p \r \o \v \e \m \e \n \t \space \i \n " ..."]]

22 May 2014 - Protalix BioTherapeutics, Inc. announced today that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval to Elelyso (taliglucerase alfa) for long-term enzyme ...

A stakeholder meeting was held on 31 July 2014 to discuss the Pharmaceutical Benefits Scheme (PBS) listing of ivacaftor (Kalydeco) ...

Public consultation on the Authority Required PBS medicines is now open and interested stakeholders can provide comments about any of ...

Data newly released by the Organisation for Economic Cooperation and Development (OECD) reveals that Australia is not matching other industrialised ...

[:content [\1 \2 \space \D \e \c \e \m \b \e \r \space \2 \0 \1 \3 \space \- \  \F \i \g \u \r \e \s \space \c \o \n \t \a \i \n \e \d \space \i \n \space \a \space \r \e \p \o \r \t \space \r \e \l \e \a \s \e \d \space \t \h \i \s \space \w \e \e \k \space \b \y \space \t \h \e \space \P \a \r \l \i \a \m \e \n \t \a \r \y \space \B \u \d \g \e \t \space \O \f \f \i \c \e \space \c \o \n \f \i \r \m \space \t \h \a \t \space \t \h \e \space \P \h \a \r \m \a \c \e \u \t \i \c \a \l " ..."]]

The Simplified Price Disclosure page has been updated. The page now includes an explanation of the steps for the price disclosure calculation ...

[:content [\T \h \e \space \A \f \f \o \r \d \a \b \l \e \space \C \a \r \e \space \A \c \t \space \o \f \f \e \r \s \space \s \t \r \o \n \g \space \s \u \p \p \o \r \t \space \f \o \r \space \c \o \m \p \a \r \a \t \i \v \e \space \e \f \f \e \c \t \i \v \e \n \e \s \s \space \r \e \s \e \a \r \c \h \, \space \w \h \i \c \h \space \e \n \t \a \i \l \s \space \c \o \m \p \a \r \i \s \o \n \s \space \a \m \o \n \g \space \a \c \t \i \v \e \space \t \r \e \a \t \m \e \n \t \s \, \space \t \o \space \p \r \o \v \i \d \e \space \t \h \e " ..."]]

[:content [\N \I \C \E \space \h \a \s \space \p \u \b \l \i \s \h \e \d \  \f \i \n \a \l \space \d \r \a \f \t \space \g \u \i \d \a \n \c \e \space \r \e \c \o \m \m \e \n \d \i \n \g \space \a \f \l \i \b \e \r \c \e \p \t \  \s \o \l \u \t \i \o \n \space \f \o \r \space \i \n \j \e \c \t \i \o \n \  \a \s \space \a \n \space \o \p \t \i \o \n \space \f \o \r \space \t \r \e \a \t \i \n \g \space \w \e \t \space \a \g \e \- \r \e \l \a \t \e \d \space \m \a \c \u \l \a \r \space \d \e \g \e \n \e \r \a \t \i \o \n \space \( \A \M \D \) \. \  \A \f \l \i \b \e \r \c \e \p \t \space \i \s \space \r \e \c \o \m \m \e \n \d \e \d " ..."]]

[:content [\I \n \t \e \r \e \s \t \i \n \g \space \e \d \i \t \o \r \i \a \l \space \b \y \space \A \l \a \n \space \M \a \y \n \a \r \d \space \i \n \space \t \h \e \space \M \a \y \space \2 \0 \1 \3 \space \i \s \s \u \e \space \o \f \space \P \h \a \r \m \a \c \o \E \c \o \n \o \m \i \c \s \. " ..."]]

Big drug companies have come under fire from the Federal Government for pushing expensive cancer medications that have limited benefit. ...